Blog
RSS FeedPosted by Michael Wonder on 18 Dec 2018
Proposal to amend the distribution and access criteria for dasatinib (Sprycel)
18 December 2018 - PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for ...
Posted by Michael Wonder on 16 Dec 2018
Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH
14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...
Posted by Michael Wonder on 11 Dec 2018
Decision to list a new brand of iron polymaltose (Ferrosig)
11 December 2018 - PHARMAC is pleased to announce a decision to list a new brand of iron polymaltose inj ...
Posted by Michael Wonder on 10 Dec 2018
Proposal to open access to atomoxetine and change funded brand
10 December 2018 - PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the ...
Posted by Michael Wonder on 07 Dec 2018
Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
7 December 2018 - PHARMAC is seeking feedback on a multi-product proposal with Merck Sharpe & Dohme. ...
Posted by Michael Wonder on 30 Nov 2018
Proposal involving treatments for multiple sclerosis, narcolepsy and attention deficit hyperactivity disorder
30 November 2018 - PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with ...
Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...
Posted by Michael Wonder on 06 Sep 2018
Proposal on the funding of infliximab, rituximab and tocilizumab
6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule. ...
Posted by Michael Wonder on 30 Aug 2018
Proposal to list sapropterin for use in pregnancy by women with phenylketonuria
30 August 2018 - PHARMAC is seeking feedback on a proposal to fund sapropterin tablets, a treatment for the rare ...
Posted by Michael Wonder on 29 Aug 2018
Proposal to move to one funded brand of lamotrigine (Logem)
29 August 2018 - PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used ...
Posted by Michael Wonder on 27 Aug 2018
Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
27 August 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and ...
Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...
Posted by Michael Wonder on 20 Aug 2018
Proposal to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
20 August 2018 - PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding ...
Posted by Michael Wonder on 01 Aug 2018
Free access plan for 'revolutionary' drug that could eliminate Hepatitis C by 2030
1 August 2018 - What has been called a "revolutionary" hepatitis C drug could soon be available free-of-charge to all ...